A new device to prop open heart arteries after interventions to unclog them adapts over time to allow restoration of the ...

Elixir Medical's DynamX bioadaptor, introduced as a potential game-changer in heart artery treatments, adapts over time to restore the artery's natural motion. A study showed it leads to fewer ...

Threats: Intense competition and patent expirations leading to generic competition.

The FDA rejected sotagliflozin 5 years ago for the same indication but for the broader population of adults with T1D, due to ...

The third-quarter earnings season was at its peak this week for large drugmakers, with several companies — Eli Lilly LLY, Merck MRK, Pfizer PFE, AbbVie ABBV and Novartis NVS — announcing their results ...

The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the ...

Boehringer and Eli Lilly have moved closer to a heart failure indication for their SGLT2 inhibitor Jardiance, as the FDA starts a fast-track review of the drug in its first use beyond diabetes.

A new survey shows that three Big Pharmas have stolen the hearts of patient groups representing nearly 1 million people with cardiovascular conditions. | A new survey shows that three Big Pharmas have ...

Mounjaro sales more than doubled to $3.11 billion from $1.41 billion a year ago. The U.S. pharma giant reported third-quarter ...

On Halloween, Lexicon was haunted again as an FDA advisory committee voted 11-3 to reject Zynquista as an accompanying ...

Ladies and gentlemen, thank you for standing-by, and welcome to the Lilly Q3 2024 Earnings Call. [Operator Instructions] I ...

Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) were down 0.7% during mid-day trading on Friday after Barclays lowered their price target on the stock from $1,025.00 to $975.00. Barclays ...